Evidence map›Paper›PMID 34474987›Full record

ArticleJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2022

A comparison of clinic and home spirometry as longtudinal outcomes in cystic fibrosis.

Alex Paynter, Umer Khan, Sonya L Heltshe, Christopher H Goss, Noah Lechtzin, Nicole Mayer Hamblett

Open access · greenAbstract readComparative Study
In one paragraph

Article in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Unsupervised home spirometryEuropean respiratory review : an official journal of the European Respiratory Society · 2023
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Transforming Care Models in Cystic Fibrosis: A Review.Healthcare (Basel, Switzerland) · 2025
    Review
  7. An alternative view of changes in lung function among people with cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Baseline-dependent improvement in CF studies, plausibility of bias.Contemporary clinical trials communications · 2024
    Article
  15. Digital twins for chronic lung diseases.European respiratory review : an official journal of the European Respiratory Society · 2024
    Review
  16. Impact of day-to-day variation in FEV1 on measures of change: A conceptual description.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2024
    Article
  17. Quantifying variation in home spirometry in people with cystic fibrosis during baseline health, and associations with clinical outcomes.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Alex PaynterCystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute. Electronic address: alex.paynter@seattlechildrens.org.
Umer KhanCystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute.
Sonya L HeltsheCystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute; Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA.
Christopher H GossCystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute; Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA; University of Washington School of Medicine, Seattle, WA, USA.
Noah LechtzinJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Nicole Mayer HamblettCystic Fibrosis Therapeutics Development Network Coordinating Center, Seattle Children's Research Institute; Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA; Department of Biostatistics, University of Washington, Seattle, WA, USA.
University of Washington · USCystic Fibrosis Foundation · USJohns Hopkins University · US

Funding

Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0M
Institute of Translational Health SciencesUL1TR000423 · NCATS · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2012 to 2016
$49.4M
Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss · 2010 to 2026
$21.4M
Proof of Principle Evaluation of IV Gallium Nitrate in Patients with CFUM1HL119073 · NHLBI · UNIVERSITY OF WASHINGTON · PI GOSS, CHRISTOPHER HOOPER, SINGH, PRADEEP K · 2013 to 2017
$4.8M
Early Intervention in Pulmonary Exacerbation in CFR01HL103965 · NHLBI · UNIVERSITY OF WASHINGTON · PI GOSS, CHRISTOPHER HOOPER, LECHTZIN, NOAH · 2010 to 2014
$3.8M
OPTIMIZE - DCCU01HL114589 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI HAMBLETT, NICOLE MAYER · 2013 to 2017
$3.3M
A Phase 1b, Multi-center Study of IV Gallium Nitrate in Patients with Cystic Fibrosis who are colonized with Nontuberculosis Mycobacterium (The ABATE Study).R01FD006848 · FDA · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss, JERRY A NICK · 2020 to 2026
$3.1M
Phase 2 Study of Intravenous Gallium Nitrate in the Treatment of Cystic FibrosisR01FD003704 · FDA · UNIVERSITY OF WASHINGTON · PI GOSS, CHRISTOPHER HOOPER · 2009 to 2018
$2.0M
FDA HHS R01 FD003704FDA HHS R01 FD006848NCATS NIH HHS UL1 TR000423NCATS NIH HHS UL1 TR002319NHLBI NIH HHS R01 HL103965NHLBI NIH HHS U01 HL114589NHLBI NIH HHS UM1 HL119073NIDDK NIH HHS P30 DK089507
6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic has accelerated the transition to telehealth, including the use of home spirometry in cystic fibrosis. Evaluating the accuracy and precision of longitudinal home spirometry is a requisite for telehealth-based research. This secondary analysis of a CF study (eICE) evaluates whether there are cross-sectional or longitudinal differences between home and clinic spirometry.

methodsParticipants age ≥14 years with ppFEV

resultsHome spirometry is estimated to be 2.0 (95% CI: 0.3, 3.5) percentage points lower than clinic spirometry cross-sectionally. Longitudinally, the estimates of 12-month change in home spirometry varied by analysis method from -2.6 to -1.0 ppFEV

conclusionsTo leverage the potential cost, feasibility and convenience of home spirometry, the differences with clinic spirometry must be acknowledged. Significantly lower ppFEV

Indexed as

AdolescentAdultCOVID-19Cross-Sectional StudiesCystic FibrosisFemaleHumansLongitudinal StudiesMalePandemicsPatient ComplianceSARS-CoV-2SpirometryTelemedicineYoung AdultCF outcome measuresCoronavirusCOVID-19Forced expiratory volume in one second (FEV1)Remote monitoringTelehealth

Identifiers

PMID34474987
PMCPMC8464351
OpenAlexW3197061111

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.